Plasma Endocannabinoid Levels in Patients with Borderline Personality Disorder and Healthy Controls
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Participants
4.2. Blood Sampling
4.3. Questionnaires
4.4. Statistics
4.5. FAAH-Genotyping
4.6. Mass Spectrometry of Anandamide
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Guilé, J.M.; Boissel, L.; Alaux-Cantin, S.; de La Rivière, S.G. Borderline personality disorder in adolescents: Prevalence, diagnosis, and treatment strategies. Adolesc. Health Med. Ther. 2018, 9, 199–210. [Google Scholar] [CrossRef] [PubMed]
- Bell, C.C. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. JAMA J. Am. Med. Assoc. 1994, 272, 828. [Google Scholar] [CrossRef]
- Wagner, T.; Fydrich, T.; Stiglmayr, C.; Marschall, P.; Salize, H.-J.; Renneberg, B.; Fleßa, S.; Roepke, S. Societal cost-of-illness in patients with borderline personality disorder one year before, during and after dialectical behavior therapy in routine outpatient care. Behav. Res. Ther. 2014, 61, 12–22. [Google Scholar] [CrossRef] [PubMed]
- Nock, M.K.; Park, J.M.; Finn, C.T.; Deliberto, T.L.; Dour, H.J.; Banaji, M.R. Measuring the Suicidal Mind. Psychol. Sci. 2010, 21, 511–517. [Google Scholar] [CrossRef]
- Brown, R.C.; Fischer, T.; Goldwich, A.D.; Keller, F.; Young, R.; Plener, P.L. #cutting: Non-suicidal self-injury (NSSI) on Instagram. Psychol. Med. 2018, 48, 337–346. [Google Scholar] [CrossRef] [PubMed]
- Whitlock, J.; Knox, K.L. The Relationship Between Self-injurious Behavior and Suicide in a Young Adult Population. Arch. Pediatr. Adolesc. Med. 2007, 161, 634. [Google Scholar] [CrossRef] [PubMed]
- Young, R.; Sproeber, N.; Groschwitz, R.C.; Preiss, M.; Plener, P.L. Why alternative teenagers self-harm: Exploring the link between non-suicidal self-injury, attempted suicide and adolescent identity. BMC Psychiatry 2014, 14, 137. [Google Scholar] [CrossRef] [PubMed]
- Ghinea, D.; Fuchs, A.; Parzer, P.; Koenig, J.; Resch, F.; Kaess, M. Psychosocial functioning in adolescents with non-suicidal self-injury: The roles of childhood maltreatment, borderline personality disorder and depression. Borderline Pers. Disord. Emot. Dysregul 2021, 8, 21. [Google Scholar] [CrossRef]
- Golier, J.A.; Yehuda, R.; Bierer, L.M.; Mitropoulou, V.; New, A.S.; Schmeidler, J.; Silverman, J.M.; Siever, L.J. The Relationship of Borderline Personality Disorder to Posttraumatic Stress Disorder and Traumatic Events. Am. J. Psychiatry 2003, 160, 2018–2024. [Google Scholar] [CrossRef]
- Sansone, R.A.; Sansone, L.A. Borderline personality and criminality. Psychiatry 2009, 6, 16–20. [Google Scholar]
- Kaess, M.; Hooley, J.M.; Klimes-Dougan, B.; Koenig, J.; Plener, P.L.; Reichl, C.; Robinson, K.; Schmahl, C.; Sicorello, M.; Schreiner, M.W.; et al. Advancing a temporal framework for understanding the biology of nonsuicidal self-injury: An expert review. Neurosci. Biobehav. Rev. 2021, 130, 228–239. [Google Scholar] [CrossRef] [PubMed]
- Koenig, J.; Rinnewitz, L.; Warth, M.; Hillecke, T.K.; Brunner, R.; Resch, F.; Kaess, M. Psychobiological response to pain in female adolescents with nonsuicidal self-injury. J. Psychiatry Neurosci. 2017, 42, 189–199. [Google Scholar] [CrossRef] [PubMed]
- Schmahl, C.; Greffrath, W.; Baumgärtner, U.; Schlereth, T.; Magerl, W.; Philipsen, A.; Lieb, K.; Bohus, M.; Treede, R.-D. Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: Laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain 2004, 110, 470–479. [Google Scholar] [CrossRef] [PubMed]
- Schmahl, C.; Bohus, M.; Esposito, F.; Treede, R.-D.; Di Salle, F.; Greffrath, W.; Ludaescher, P.; Jochims, A.; Lieb, K.; Scheffler, K.; et al. Neural Correlates of Antinociception in Borderline Personality Disorder. Arch. Gen. Psychiatry 2006, 63, 659. [Google Scholar] [CrossRef] [PubMed]
- Degasperi, G.; Cristea, I.A.; Di Rosa, E.; Costa, C.; Gentili, C. Parsing variability in borderline personality disorder: A meta-analysis of neuroimaging studies. Transl. Psychiatry 2021, 11, 314. [Google Scholar] [CrossRef]
- Weld, K.P.; Mench, J.A.; Woodward, R.A.; Bolesta, M.S.; Suomi, S.J.; Higley, J.D. Effect of Tryptophan Treatment on Self-Biting and Central Nervous System Serotonin Metabolism in Rhesus Monkeys (Macaca mulatta). Neuropsychopharmacology 1998, 19, 314–321. [Google Scholar] [CrossRef]
- Stefan, T.; Tiefenbacher, S.; Novak, M.A.; Lutz, C.K.; Meyer, J.S. The physiology and neurochemistry of self-injurious behavior: A nonhuman primate model. Front. Biosci. 2005, 10, 1–11. [Google Scholar] [CrossRef]
- Blasco-Fontecilla, H.; Fernández-Fernández, R.; Colino, L.; Fajardo, L.; Perteguer-Barrio, R.; de Leon, J. The Addictive Model of Self-Harming (Non-suicidal and Suicidal) Behavior. Front. Psychiatry 2016, 7, 8. [Google Scholar] [CrossRef]
- Viveros, M.; Marco, E.M.; File, S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol. Biochem. Behav. 2005, 81, 331–342. [Google Scholar] [CrossRef]
- Berardi, A.; Schelling, G.; Campolongo, P. The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings. Pharmacol. Res. 2016, 111, 668–678. [Google Scholar] [CrossRef]
- McLaughlin, R.J.; Hill, M.N.; Gorzalka, B.B. A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior. Neurosci. Biobehav. Rev. 2014, 42, 116–131. [Google Scholar] [CrossRef] [PubMed]
- Moreira, F.A.; Wotjak, C.T. Cannabinoids and Anxiety. Curr. Top. Behav. Neurosci. 2009, 2, 429–450. [Google Scholar] [CrossRef]
- Mayo, L.M.; Asratian, A.; Lindé, J.; Morena, M.; Haataja, R.; Hammar, V.; Augier, G.; Hill, M.N.; Heilig, M. Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial. Biol. Psychiatry 2020, 87, 538–547. [Google Scholar] [CrossRef] [PubMed]
- Spohrs, J.; Ulrich, M.; Grön, G.; Prost, M.; Plener, P.L.; Fegert, J.M.; Bindila, L.; Abler, B. Fear extinction learning and anandamide: An fMRI study in healthy humans. Transl. Psychiatry 2021, 11, 161. [Google Scholar] [CrossRef] [PubMed]
- Spohrs, J.; Ulrich, M.; Grön, G.; Plener, P.L.; Abler, B. FAAH polymorphism (rs324420) modulates extinction recall in healthy humans: An fMRI study. Eur. Arch. Psychiatry Clin. Neurosci. 2021, 272, 1495–1504. [Google Scholar] [CrossRef] [PubMed]
- Schmitt, M.; Baumert, A.; Gollwitzer, M.; Maes, J. The Justice Sensitivity Inventory: Factorial Validity, Location in the Personality Facet Space, Demographic Pattern, and Normative Data. Soc. Justice Res. 2010, 23, 211–238. [Google Scholar] [CrossRef]
- Siep, N.; Tonnaer, F.; van de Ven, V.; Arntz, A.; Raine, A.; Cima, M. Anger provocation increases limbic and decreases medial prefrontal cortex connectivity with the left amygdala in reactive aggressive violent offenders. Brain Imaging Behav. 2019, 13, 1311–1323. [Google Scholar] [CrossRef] [PubMed]
- Hariri, A.R.; Gorka, A.; Hyde, L.W.; Kimak, M.; Halder, I.; Ducci, F.; Ferrell, R.E.; Goldman, D.; Manuck, S.B. Divergent Effects of Genetic Variation in Endocannabinoid Signaling on Human Threat- and Reward-Related Brain Function. Biol. Psychiatry 2009, 66, 9–16. [Google Scholar] [CrossRef]
- Bossong, M.G.; van Hell, H.H.; Jager, G.; Kahn, R.S.; Ramsey, N.F.; Jansma, J.M. The endocannabinoid system and emotional processing: A pharmacological fMRI study with ∆9-tetrahydrocannabinol. Eur. Neuropsychopharmacol. 2013, 23, 1687–1697. [Google Scholar] [CrossRef]
- Phan, K.L.; Angstadt, M.; Golden, J.; Onyewuenyi, I.; Popovska, A.; de Wit, H. Cannabinoid Modulation of Amygdala Reactivity to Social Signals of Threat in Humans. J. Neurosci. 2008, 28, 2313–2319. [Google Scholar] [CrossRef]
- Schaefer, C.; Enning, F.; Mueller, J.K.; Bumb, J.M.; Rohleder, C.; Odorfer, T.M.; Klosterkötter, J.; Hellmich, M.; Koethe, D.; Schmahl, C.; et al. Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264, 459–463. [Google Scholar] [CrossRef] [PubMed]
- Wingenfeld, K.; Dettenborn, L.; Kirschbaum, C.; Gao, W.; Otte, C.; Roepke, S. Reduced levels of the endocannabinoid arachidonylethanolamide (AEA) in hair in patients with borderline personality disorder—A pilot study. Stress 2018, 21, 366–369. [Google Scholar] [CrossRef] [PubMed]
- Vest, N.A.; Murphy, K.T.; Tragesser, S.L. Borderline personality disorder features and drinking, cannabis, and prescription opioid motives: Differential associations across substance and sex. Addict. Behav. 2018, 87, 46–54. [Google Scholar] [CrossRef] [PubMed]
- Regier, D.A.; Farmer, M.E.; Rae, D.S.; Locke, B.Z.; Keith, S.J.; Judd, L.L.; Goodwin, F.K. Comorbidity of Mental Disorders with Alcohol and Other Drug Abuse. JAMA 1990, 264, 2511. [Google Scholar] [CrossRef] [PubMed]
- Lutz, B.; Marsicano, G.; Maldonado, R.; Hillard, C.J. The endocannabinoid system in guarding against fear, anxiety and stress. Nature Reviews Neuroscience; Nature Publishing Group: Berlin, Germany, 2015; Volume 16, pp. 705–718. [Google Scholar] [CrossRef]
- Nyilas, R.; Dudok, B.; Urbán, G.M.; Mackie, K.; Watanabe, M.; Cravatt, B.F.; Freund, T.F.; Katona, I. Enzymatic Machinery for Endocannabinoid Biosynthesis Associated with Calcium Stores in Glutamatergic Axon Terminals. J. Neurosci. 2008, 28, 1058–1063. [Google Scholar] [CrossRef] [PubMed]
- Kano, M.; Ohno-Shosaku, T.; Hashimotodani, Y.; Uchigashima, M.; Watanabe, M. Endocannabinoid-Mediated Control of Synaptic Transmission. Physiol. Rev. 2009, 89, 309–380. [Google Scholar] [CrossRef] [PubMed]
- Howlett, A.C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002, 68–69, 619–631. [Google Scholar] [CrossRef]
- Ahn, K.; McKinney, M.K.; Cravatt, B.F. Enzymatic Pathways That Regulate Endocannabinoid Signaling in the Nervous System. Chem. Rev. 2008, 108, 1687–1707. [Google Scholar] [CrossRef]
- Bisogno, T.; Maccarrone, M. Latest advances in the discovery of fatty acid amide hydrolase inhibitors. Expert. Opin. Drug Discov. 2013, 8, 509–522. [Google Scholar] [CrossRef]
- Boileau, I.; Tyndale, R.F.; Williams, B.; Mansouri, E.; Westwood, D.J.; Le Foll, B.; Rusjan, P.M.; Mizrahi, R.; De Luca, V.; Zhou, Q.; et al. The Fatty Acid Amide Hydrolase C385A Variant Affects Brain Binding of the Positron Emission Tomography Tracer [11C]CURB. J. Cereb. Blood Flow. Metab. 2015, 35, 1237–1240. [Google Scholar] [CrossRef]
- Chiang, K.P.; Gerber, A.L.; Sipe, J.C.; Cravatt, B.F. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: Evidence for a link between defects in the endocannabinoid system and problem drug use. Hum. Mol. Genet. 2004, 13, 2113–2119. [Google Scholar] [CrossRef]
- Dincheva, I.; Drysdale, A.T.; Hartley, C.A.; Johnson, D.C.; Jing, D.; King, E.C.; Ra, S.; Gray, J.M.; Yang, R.; DeGruccio, A.M.; et al. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat. Commun. 2015, 6, 6395. [Google Scholar] [CrossRef] [PubMed]
- Mayo, L.M.; Asratian, A.; Lindé, J.; Holm, L.; Nätt, D.; Augier, G.; Stensson, N.; Vecchiarelli, H.A.; Balsevich, G.; Aukema, R.J.; et al. Protective effects of elevated anandamide on stress and fear-related behaviors: Translational evidence from humans and mice. Mol. Psychiatry 2020, 25, 993–1005. [Google Scholar] [CrossRef] [PubMed]
- Gunduz-Cinar, O.; MacPherson, K.P.; Cinar, R.; Gamble-George, J.; Sugden, K.; Williams, B.; Godlewski, G.; Ramikie, T.S.; Gorka, A.X.; Alapafuja, S.O.; et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol. Psychiatry 2013, 18, 813–823. [Google Scholar] [CrossRef] [PubMed]
- Spagnolo, P.A.; Ramchandani, V.A.; Schwandt, M.L.; Kwako, L.E.; George, D.T.; Mayo, L.M.; Hillard, C.J.; Heilig, M. FAAH Gene Variation Moderates Stress Response and Symptom Severity in Patients with Posttraumatic Stress Disorder and Comorbid Alcohol Dependence. Alcohol. Clin. Exp. Res. 2016, 40, 2426–2434. [Google Scholar] [CrossRef]
- Hauer, D.; Schelling, G.; Gola, H.; Campolongo, P.; Morath, J.; Roozendaal, B.; Hamuni, G.; Karabatsiakis, A.; Atsak, P.; Vogeser, M.; et al. Plasma Concentrations of Endocannabinoids and Related Primary Fatty Acid Amides in Patients with Post-Traumatic Stress Disorder. PLoS ONE 2013, 8, e62741. [Google Scholar] [CrossRef]
- Neumeister, A.; Normandin, M.D.; Pietrzak, R.H.; Piomelli, D.; Zheng, M.Q.; Gujarro-Anton, A.; Potenza, M.N.; Bailey, C.R.; Lin, S.F.; Najafzadeh, S.; et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: A positron emission tomography study. Mol. Psychiatry 2013, 18, 1034–1040. [Google Scholar] [CrossRef]
- Kolla, N.J.; Mizrahi, R.; Karas, K.; Wang, C.; Bagby, R.M.; McMain, S.; Simpson, A.I.; Rusjan, P.M.; Tyndale, R.; Houle, S.; et al. Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: A [11C]CURB positron emission tomography study. Neuropsychopharmacology 2020, 45, 1834–1841. [Google Scholar] [CrossRef]
- Woodhams, S.G.; Chapman, V.; Finn, D.P.; Hohmann, A.G.; Neugebauer, V. The cannabinoid system and pain. Neuropharmacology 2017, 124, 105–120. [Google Scholar] [CrossRef]
- Bedse, G.; Bluett, R.J.; Patrick, T.A.; Romness, N.K.; Gaulden, A.D.; Kingsley, P.J.; Plath, N.; Marnett, L.J.; Patel, S. Therapeutic endocannabinoid augmentation for mood and anxiety disorders: Comparative profiling of FAAH, MAGL and dual inhibitors. Transl. Psychiatry 2018, 8, 92. [Google Scholar] [CrossRef]
- Mayo, L.M.; Rabinak, C.A.; Hill, M.N.; Heilig, M. Targeting the Endocannabinoid System in the Treatment of Posttraumatic Stress Disorder: A Promising Case of Preclinical-Clinical Translation? Biol. Psychiatry 2022, 91, 262–272. [Google Scholar] [CrossRef] [PubMed]
- Stoffers-Winterling, J.M.; Völlm, B.A.; Rücker, G.; Timmer, A.; Huband, N.; Lieb, K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst. Rev. 2012, 2020, CD005652. [Google Scholar] [CrossRef]
- Gartlehner, G.; Crotty, K.; Kennedy, S.; Edlund, M.J.; Ali, R.; Siddiqui, M.; Fortman, R.; Wines, R.; Persad, E.; Viswanathan, M. Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis. CNS Drugs 2021, 35, 1053–1067. [Google Scholar] [CrossRef] [PubMed]
- Hillard, C.J.; Beatka, M.; Sarvaideo, J. Endocannabinoid Signaling and the Hypothalamic-Pituitary-Adrenal Axis. Compr. Physiol. 2016, 7, 1–15. [Google Scholar] [CrossRef]
- Hill, M.N.; Hillard, C.J.; Bambico, F.R.; Patel, S.; Gorzalka, B.B.; Gobbi, G. The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants. Trends Pharmacol. Sci. 2009, 30, 484–493. [Google Scholar] [CrossRef] [PubMed]
- Gorzalka, B.B.; Hill, M.N. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35, 1575–1585. [Google Scholar] [CrossRef] [PubMed]
- Hill, M.N.; Miller, G.E.; Carrier, E.J.; Gorzalka, B.B.; Hillard, C.J. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 2009, 34, 1257–1262. [Google Scholar] [CrossRef]
- Behnke, A.; Gumpp, A.M.; Rojas, R.; Sänger, T.; Lutz-Bonengel, S.; Moser, D.; Schelling, G.; Krumbholz, A.; Kolassa, I.-T. Circulating inflammatory markers, cell-free mitochondrial DNA, cortisol, endocannabinoids, and N-acylethanolamines in female depressed outpatients. World J. Biol. Psychiatry 2023, 24, 58–69. [Google Scholar] [CrossRef]
- Walther, A.; Kirschbaum, C.; Wehrli, S.; Rothe, N.; Penz, M.; Wekenborg, M.; Gao, W. Depressive symptoms are negatively associated with hair N-arachidonoylethanolamine (anandamide) levels: A cross-lagged panel analysis of four annual assessment waves examining hair endocannabinoids and cortisol. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2023, 121, 110658. [Google Scholar] [CrossRef]
- Galve-Roperh, I.; Palazuelos, J.; Aguado, T.; Guzmán, M. The endocannabinoid system and the regulation of neural development: Potential implications in psychiatric disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259, 371–382. [Google Scholar] [CrossRef]
- Horder, J.; Harmer, C.J.; Cowen, P.J.; McCabe, C. Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers. Int. J. Neuropsychopharmacol. 2010, 13, 1103–1113. [Google Scholar] [CrossRef] [PubMed]
- Gorzalka, B.B.; Hill, M.N.; Hillard, C.J. Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders. Neurosci. Biobehav. Rev. 2008, 32, 1152–1160. [Google Scholar] [CrossRef] [PubMed]
- Sugamura, K.; Sugiyama, S.; Nozaki, T.; Matsuzawa, Y.; Izumiya, Y.; Miyata, K.; Nakayama, M.; Kaikita, K.; Obata, T.; Takeya, M.; et al. Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages. Circulation 2009, 119, 28–36. [Google Scholar] [CrossRef] [PubMed]
- Boscarino, J.A. A Prospective Study of PTSD and Early-Age Heart Disease Mortality Among Vietnam Veterans: Implications for Surveillance and Prevention. Psychosom. Med. 2008, 70, 668–676. [Google Scholar] [CrossRef] [PubMed]
- Loranger, A.; Janca, A.; Sartorius, N. Assessment and Diagnosis of Personality Disorders: The ICD-10 International Personality Disorder Examination (IPDE); Cambridge University Press: Cambridge, UK, 1997. [Google Scholar]
- Lerner, R.; Post, J.; Loch, S.; Lutz, B.; Bindila, L. Targeting brain and peripheral plasticity of the lipidome in acute kainic acid-induced epileptic seizures in mice via quantitative mass spectrometry. Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids 2017, 1862, 255–267. [Google Scholar] [CrossRef]
- Bohus, M.; Kleindienst, N.; Limberger, M.F.; Stieglitz, R.-D.; Domsalla, M.; Chapman, A.L.; Steil, R.; Philipsen, A.; Wolf, M. The Short Version of the Borderline Symptom List (BSL-23): Development and Initial Data on Psychometric Properties. Psychopathology 2009, 42, 32–39. [Google Scholar] [CrossRef]
- Hautzinger, M.; Keller, F.; Kühner, C. Beck-Depressions-Inventar; Hogrefe: Oxford, UK, 2009. [Google Scholar]
- Laux, L.; Glanzmann, P.; Schaffner, P.; Spielberger, C. Das Stait-Trait-Angstinventar; Beltz: Weinheim, Germany, 1981. [Google Scholar]
- Post, J.M.; Loch, S.; Lerner, R.; Remmers, F.; Lomazzo, E.; Lutz, B.; Bindila, L. Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy. Front. Mol. Neurosci. 2018, 11, 67. [Google Scholar] [CrossRef]
- Bindila, L.; Lutz, B. Extraction and Simultaneous Quantification of Endocannabinoids and Endocannabinoid-Like Lipids in Biological Tissues. Methods Mol. Biol. 2016, 1412, 9–18. [Google Scholar] [CrossRef]
Patients (N = 49) | Healthy Controls (N = 32) | Group Differences | |
---|---|---|---|
Gender | 42 females (85.7%) | 27 females (84.4%) | X2 = 0.03, p = 0.87 b |
FAAH_rs324420: CC/CA/AA | N = 32/14/3 | N = 18/13/1 | CC vs. CA/AA: X2 = 0.67, p = 0.41 b |
AEA levels, pmol/mL plasma (M ± SD) | 1.00 ± 0.55 | 0.68 ± 0.29 | t(79) = 2.96, p = 0.001 a |
2-AG levels, pmol/mL plasma (M ± SD) | 1.48 ± 1.69 | 0.92 ± 0.56 | t(79) = 1.80, p = 0.08 a |
Patients (N = 49) | Healthy Controls (N = 32) | Group Differences | |
---|---|---|---|
Gender | 42 females (85.7%) | 27 females (84.4%) | X2 = 0.03, p = 0.87 b |
Age (M ± SD) | 27.02 ± 10.04 [18–61 y] | 25.06 ± 3.70 [18–35 y] | t(79) = 1.05, p = 0.29 a |
Body Mass Index: kg/m2 (M ± SD) | 28.76 ± 8.19 | 26.93 ± 6.89 | t(78) = 1.03, p = 0.30 a |
Smoker (nicotine) | N = 24 (49.0%) | N = 15 (46.9%) | X2 = 0.03, p = 0.85 b |
BDI-II (M ± SD) | 37.11 ± 8.53 | 5.03 ± 3.38 | t(72) = 20.09, p < 0.001 a |
BSL sum (M ± SD) | 50.18 ± 16.02 | 2.91 ± 2.37 | t(75) = 16.54, p < 0.001 a |
Self-injury (number in the past year, M ± SD) | 60.31 ± 95.23 | ||
Number of suicide attempts (lifetime, M ± SD) | 3.11 ± 4.05 | ||
Days per week with suicidal thoughts in the past 6 months | 4.31 ± 2.36 | ||
Current psychotropic medication | Antidepressants N = 41 Antipsychotics N = 11 | ||
STAI-S sum score at blood draw (M ± SD) | 54.88 ± 9.34 | 30.47 ± 7.18 | t(78) = 12.51, p < 0.001 a |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Spohrs, J.; Kühnle, V.; Mikusky, D.; Sanhüter, N.; Macchia, A.; Nickel, S.; Abler, B. Plasma Endocannabinoid Levels in Patients with Borderline Personality Disorder and Healthy Controls. Int. J. Mol. Sci. 2023, 24, 17452. https://doi.org/10.3390/ijms242417452
Spohrs J, Kühnle V, Mikusky D, Sanhüter N, Macchia A, Nickel S, Abler B. Plasma Endocannabinoid Levels in Patients with Borderline Personality Disorder and Healthy Controls. International Journal of Molecular Sciences. 2023; 24(24):17452. https://doi.org/10.3390/ijms242417452
Chicago/Turabian StyleSpohrs, Jennifer, Valentin Kühnle, David Mikusky, Niklas Sanhüter, Ana Macchia, Sandra Nickel, and Birgit Abler. 2023. "Plasma Endocannabinoid Levels in Patients with Borderline Personality Disorder and Healthy Controls" International Journal of Molecular Sciences 24, no. 24: 17452. https://doi.org/10.3390/ijms242417452